Signaturefd LLC Buys 7,799 Shares of Bristol-Myers Squibb (NYSE:BMY)

Signaturefd LLC raised its stake in Bristol-Myers Squibb (NYSE:BMY) by 8.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 99,174 shares of the biopharmaceutical company’s stock after acquiring an additional 7,799 shares during the period. Signaturefd LLC’s holdings in Bristol-Myers Squibb were worth $5,131,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Global Assets Advisory LLC bought a new position in Bristol-Myers Squibb during the 1st quarter valued at about $5,161,000. Austin Private Wealth LLC grew its holdings in Bristol-Myers Squibb by 30.7% during the 1st quarter. Austin Private Wealth LLC now owns 6,070 shares of the biopharmaceutical company’s stock valued at $317,000 after purchasing an additional 1,427 shares during the last quarter. Wallace Advisory Group LLC grew its holdings in Bristol-Myers Squibb by 18.4% during the 1st quarter. Wallace Advisory Group LLC now owns 6,104 shares of the biopharmaceutical company’s stock valued at $313,000 after purchasing an additional 950 shares during the last quarter. Beech Hill Advisors Inc. grew its holdings in Bristol-Myers Squibb by 1.5% during the 1st quarter. Beech Hill Advisors Inc. now owns 19,118 shares of the biopharmaceutical company’s stock valued at $1,037,000 after purchasing an additional 291 shares during the last quarter. Finally, Thompson Investment Management Inc. grew its holdings in Bristol-Myers Squibb by 10.6% during the 1st quarter. Thompson Investment Management Inc. now owns 80,477 shares of the biopharmaceutical company’s stock valued at $4,364,000 after purchasing an additional 7,737 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on BMY shares. Jefferies Financial Group boosted their price objective on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the company a “hold” rating in a research report on Wednesday, August 28th. StockNews.com raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 29th. Cantor Fitzgerald reissued a “neutral” rating and issued a $50.00 price objective on shares of Bristol-Myers Squibb in a research report on Friday. TD Cowen lifted their price target on Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a “hold” rating in a report on Monday, October 7th. Finally, UBS Group increased their target price on shares of Bristol-Myers Squibb from $50.00 to $54.00 and gave the company a “neutral” rating in a research report on Wednesday, October 9th. Two investment analysts have rated the stock with a sell rating, fourteen have given a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $53.20.

Bristol-Myers Squibb Stock Performance

Shares of Bristol-Myers Squibb stock traded up $0.82 during trading on Tuesday, hitting $52.94. 1,974,786 shares of the company’s stock were exchanged, compared to its average volume of 14,643,598. The stock has a market capitalization of $107.31 billion, a price-to-earnings ratio of -16.81, a PEG ratio of 13.75 and a beta of 0.46. The business has a 50-day simple moving average of $50.46 and a 200-day simple moving average of $46.34. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $56.77. The company has a debt-to-equity ratio of 2.86, a quick ratio of 1.02 and a current ratio of 1.16.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, beating the consensus estimate of $1.64 by $0.43. The company had revenue of $12.20 billion for the quarter, compared to analyst estimates of $11.54 billion. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%. The firm’s revenue was up 8.7% on a year-over-year basis. During the same quarter last year, the business earned $1.75 earnings per share. On average, research analysts forecast that Bristol-Myers Squibb will post 0.77 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.53%. The ex-dividend date of this dividend is Friday, October 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.